{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:47:28Z","timestamp":1774320448305,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ijantimicag.2008.12.012","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T10:03:02Z","timestamp":1236160982000},"page":"1-7","source":"Crossref","is-referenced-by-count":45,"title":["Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA)"],"prefix":"10.1016","volume":"34","author":[{"given":"April","family":"Barbour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth H.","family":"Rand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Derendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2008.12.012_bib1","unstructured":"U.S. Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. Washington, DC: US Government Printing Office; September 1995. Report No. OTA-H-629."},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1378\/chest.118.1.146","article-title":"The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting","volume":"118","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-37923","article-title":"Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997\u20132001)","volume":"24","author":"Jones","year":"2003","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0732-8893(02)00499-6","article-title":"Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and antimicrobial susceptibility profile: results from the SENTRY Antimicrobial Surveillance Program (1997\u20132000)","volume":"44","author":"Gales","year":"2002","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0732-8893(00)00234-0","article-title":"Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I\u2014results from the SENTRY Antimicrobial Surveillance Program (North America, 1998)","volume":"39","author":"Mathai","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2006.12.009","article-title":"Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999\u20132004)","volume":"58","author":"Fritsche","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/527392","article-title":"Vancomycin-resistant Staphylococcus aureus in the United States, 2002\u20132006","volume":"46","author":"Sievert","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ijantimicag.2005.11.008","article-title":"Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis","volume":"27","author":"Gales","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2007.02.010","article-title":"In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection","volume":"58","author":"Rouse","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib10","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkf249","article-title":"In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci","volume":"50","author":"Jones","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diagmicrobio.2008.02.008","article-title":"Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005\u20132006)","volume":"61","author":"Fritsche","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.45.3.825-836.2001","article-title":"In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci","volume":"45","author":"Hebeisen","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib13","unstructured":"Janssen-Ortho Inc. Zeftera product monograph. Toronto, Canada: Janssen-Ortho Inc.; 2008."},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib14","unstructured":"Barbour A, Murthy B, Schmidt S, Sabarinath S, Skee D, Tian H, et al. Soft-tissue penetration of ceftobiprole following single-dose administration in healthy adults. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 25\u201328 October 2008; Washington, DC. Washington, DC: ASM Press; 2008."},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib15","unstructured":"Murthy B, Skee D, Wexler D, Balis D, Chang I, Desai-Kreiger D, et al. Pharmacokinetics of ceftobiprole following single and multiple intravenous infusions administered to healthy subjects. In: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 31 March\u20134 April 2007; Munich, Germany. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2007 [Abstract number: 1733_277]."},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib16","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1128\/AAC.48.7.2570-2575.2004","article-title":"Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers","volume":"48","author":"Schmitt-Hoffmann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib17","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1128\/AAC.48.7.2576-2580.2004","article-title":"Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers","volume":"48","author":"Schmitt-Hoffmann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003088-200847010-00003","article-title":"Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity","volume":"47","author":"Murthy","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib20","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1128\/AAC.48.9.3419-3424.2004","article-title":"Effect of ertapenem protein binding on killing of bacteria","volume":"48","author":"Nix","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/jac\/dkm524","article-title":"Plasma protein binding of fluoroquinolones affects antimicrobial activity","volume":"61","author":"Zeitlinger","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/jac\/dkl284","article-title":"Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis","volume":"58","author":"Burkhardt","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib23","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.43.10.2345","article-title":"Penetration of moxifloxacin into peripheral compartments in humans","volume":"43","author":"Muller","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib24","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1128\/AAC.00532-07","article-title":"Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis","volume":"51","author":"Traunmuller","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1389201023378373","article-title":"Human microdialysis","volume":"3","author":"Stahl","year":"2002","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib26","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/0024-3205(91)90488-W","article-title":"Drug distribution studies with microdialysis. III: extracellular concentration of caffeine in adipose tissue in man","volume":"49","author":"Stahle","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib27","unstructured":"Schmitt-Hoffmann AH, Harsch M, Heep M, Schleimer M, Brown T, Man A, et al. BAL5788 in patients with complicated skin and skin structure infections cause by Gram-positive pathogens including methicillin-resistant Staphylococcus species. Interim pharmacokinetic results from 20 patients. In: 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 1\u20134 May 2004; Prague, Czech Republic. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2004."},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib29","unstructured":"Schmitt-Hoffmann A. Influence of gender on the pharmacokinetics of BAL9141 after intravenous infusion of pro-drug BAL5788. In: 14th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 1\u20134 May 2004; Prague, Czech Republic. Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases; 2004."},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.diagmicrobio.2004.04.011","article-title":"Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates","volume":"50","author":"Deshpande","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib31","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1128\/AAC.00238-06","article-title":"Activities of ceftobiprole and other \u03b2-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2\u00d7","volume":"50","author":"Davies","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib32","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1128\/AAC.00029-07","article-title":"Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae","volume":"51","author":"Davies","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib33","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1128\/AAC.00218-07","article-title":"Interactions of ceftobiprole with \u03b2-lactamases from molecular classes A to D","volume":"51","author":"Queenan","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib34","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1128\/AAC.00044-06","article-title":"Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis","volume":"50","author":"Bogdanovich","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib35","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1046\/j.1469-0691.2003.00765.x","article-title":"Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci","volume":"9","author":"Deshpande","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib36","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1128\/AAC.49.10.4210-4219.2005","article-title":"Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin","volume":"49","author":"Bogdanovich","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1128\/AAC.48.4.1105-1111.2004","article-title":"Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia","volume":"48","author":"Azoulay-Dupuis","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib38","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/AAC.49.3.884-888.2005","article-title":"Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus","volume":"49","author":"Chambers","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/jac\/dkm237","article-title":"Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model","volume":"60","author":"Arias","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib40","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","article-title":"National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections","volume":"168","author":"Hersh","year":"2008","journal-title":"Arch Intern Med"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2008.12.012_bib41","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib42","unstructured":"Andes D, Craig W. In-vivo pharmacodynamics of RO 63-9141 against multiple bacterial pathogens. In: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 17\u201320 September 2000; Toronto, Canada. Washington, DC: ASM Press; 2000."},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/jac\/dki335","article-title":"Comparison of \u03b2-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics\/pharmacodynamics","volume":"56","author":"Burgess","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib44","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1128\/AAC.48.5.1713-1718.2004","article-title":"Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141","volume":"48","author":"Mouton","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2008.12.012_bib45","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1128\/AAC.01181-06","article-title":"Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857909000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,18]],"date-time":"2019-05-18T11:35:51Z","timestamp":1558179351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857909000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0924857909000235"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2008.12.012","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}